FDA’s top gene therapy regulator is leaving his role
11 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
The brief
"FDA’s top gene therapy regulator is leaving his role" is generating significant coverage in the Business category, with 12 articles from 11 distinct sources tracked by PULSE so far.
Outlets currently covering the story include Yahoo, TradingView, PharmTech.com and GlobeNewswire. PULSE measures a story's velocity from how quickly new articles appear and how many independent newsrooms join the coverage.
This brief was generated by PULSE's extractive engine from coverage metadata only. The latest headlines from every source are listed below; the velocity chart shows how the story is developing in real time.
Generated by PULSE's extractive engine from coverage metadata only — no AI-written claims. Updated 135d ago.
Quick answers
Why is "FDA’s top gene therapy regulator is leaving his role" trending?
Because 11 independent news sources published 12 articles about it in a short window — a coverage burst PULSE classifies as a trend.
How does PULSE measure this trend?
PULSE scores velocity from the rate of new articles weighted by source diversity, snapshotted hourly. The full method is public on our methodology page.
Is this trend still active?
The status badge on this page updates hourly: rising, peaking, cooling, or archived once coverage stops for 48 hours.
Coverage (12)
- US FDA rejects approval of Unicycive’s kidney disease therapy Yahoo · 138d ago
- UNCY Stock Clocks Worst Day In A Year — Analysts Keep Buy Ratings Despite ‘5-12 Month Delay’ In Drug Approval TradingView · 138d ago
- Manufacturing Deficiencies Behind FDA's Oxylanthanum Carbonate Rejection PharmTech.com · 138d ago
- Unicycive Therapeutics Receives Complete Response Letter GlobeNewswire · 138d ago
- Unicycive shares plunge after FDA issues Complete Response Letter for kidney disease drug (UNCY) Yahoo Finance · 138d ago
- US FDA declines to approve Unicycive's kidney disease drug Reuters · 138d ago
- Top FDA gene and cell therapy regulator to step down BioPharma Dive · 138d ago
- FDA’s cell and gene therapy head steps down after 1 year BioSpace · 138d ago
- Top FDA gene and cell therapy regulator to step down Yahoo · 138d ago
- FDA’s acting director of cell and gene therapies to leave position Endpoints News · 138d ago
- FDA gene therapy regulator steps down from leadership role Fierce Biotech · 138d ago
- FDA’s top gene therapy regulator is leaving his role statnews.com · 138d ago
Topics
Related trends
EXCLUSIVE: US FDA shelves commissioner's voucher program for speedy drug reviews, sources say
The US FDA has shelved its commissioner's priority review voucher pilot program for expedited drug reviews, according to exclusive reporting from Reuters and coverage across multiple outlets.
Christina Applegate fears that ‘poisoning’ may be behind her misdiagnosis of MS
Christina Applegate reveals she is investigating whether breast implant illness caused her multiple sclerosis misdiagnosis, calling it potential 'poisoning.'
FDA orders new warning labels on Ozempic, Wegovy over rare risk of permanent vision loss
Federal regulators mandate new vision loss warning labels across the widely used GLP-1 receptor agonist drug class.
FDA tells GLP-1 makers to warn of potential vision loss side effect
The FDA is requiring all GLP-1 drug makers to add warnings about a possible increased risk of NAION, a rare eye condition that can cause sudden and permanent vision loss.
FDA orders new warning on GLP-1s over rare eye condition linked to sudden blindness
Federal regulators issue a new warning regarding GLP-1 medications and a rare eye condition linked to sudden blindness.
US regulator orders makers of weight-loss drugs to carry blindness risk warning
The FDA is requiring all GLP-1 drug makers to add a warning about NAION, a rare eye condition that can cause sudden blindness, to their prescribing information.